Caricamento...
Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease
INTRODUCTION: Anti-integrin therapy for the treatment of patients with Crohn’s disease is rapidly evolving. Two agents, natalizumab and vedolizumab, are approved by the United States Food and Drug Administration for the treatment of Crohn’s disease, with vedolizumab the primary anti-integrin used du...
Salvato in:
| Pubblicato in: | Expert Opin Investig Drugs |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4926164/ https://ncbi.nlm.nih.gov/pubmed/26822204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2016.1148137 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|